Physician profile
Samir Anabi
NPI 1790893857
$12,926.06
in general payments reported to CMS, 2019-2025
49 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $1,248 · 2021: $2,228 · 2022: $2,631 · 2023: $2,484 · 2024: $2,109 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,250 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,250.27 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,544.00 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $1,001.57 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $823.95 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $823.75 | 2019-2025 | |
| Novo Nordisk INC | $790.21 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $727.35 | 2019-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $686.88 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $580.40 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $447.09 | 2021-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $375.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $361.07 | 2021-2025 | |
| Esperion Therapeutics, INC. | $274.16 | 2020-2024 | Nexletol |
| Sunovion Pharmaceuticals INC. | $270.22 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $263.75 | 2021-2024 | Jynarque, Rexulti, Nuedexta |
| Portola Pharmaceuticals, LLC | $252.55 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Anabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.